Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis
Chengkai Dai, Sandro Santagata, Zijian Tang, Jiayuan Shi, Junxia Cao, Hyoungtae Kwon, Roderick T. Bronson, Luke Whitesell, Susan Lindquist
Chengkai Dai, Sandro Santagata, Zijian Tang, Jiayuan Shi, Junxia Cao, Hyoungtae Kwon, Roderick T. Bronson, Luke Whitesell, Susan Lindquist
View: Text | PDF
Research Article Oncology

Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis

  • Text
  • PDF
Abstract

Intrinsic stress response pathways are frequently mobilized within tumor cells. The mediators of these adaptive mechanisms and how they contribute to carcinogenesis remain poorly understood. A striking example is heat shock factor 1 (HSF1), master transcriptional regulator of the heat shock response. Surprisingly, we found that loss of the tumor suppressor gene neurofibromatosis type 1 (Nf1) increased HSF1 levels and triggered its activation in mouse embryonic fibroblasts. As a consequence, Nf1–/– cells acquired tolerance to proteotoxic stress. This activation of HSF1 depended on dysregulated MAPK signaling. HSF1, in turn, supported MAPK signaling. In mice, Hsf1 deficiency impeded NF1-associated carcinogenesis by attenuating oncogenic RAS/MAPK signaling. In cell lines from human malignant peripheral nerve sheath tumors (MPNSTs) driven by NF1 loss, HSF1 was overexpressed and activated, which was required for tumor cell viability. In surgical resections of human MPNSTs, HSF1 was overexpressed, translocated to the nucleus, and phosphorylated. These findings reveal a surprising biological consequence of NF1 deficiency: activation of HSF1 and ensuing addiction to this master regulator of the heat shock response. The loss of NF1 function engages an evolutionarily conserved cellular survival mechanism that ultimately impairs survival of the whole organism by facilitating carcinogenesis.

Authors

Chengkai Dai, Sandro Santagata, Zijian Tang, Jiayuan Shi, Junxia Cao, Hyoungtae Kwon, Roderick T. Bronson, Luke Whitesell, Susan Lindquist

×

Figure 6

HSF1 is overexpressed and activated in human MPNST cell lines lacking neurofibromin.

Options: View larger image (or click on image) Download as PowerPoint
HSF1 is overexpressed and activated in human MPNST cell lines lacking ne...
(A) Immunoblotting of cell lines with complete loss of neurofibromin showed elevated p–C-RAF, p-MEK1/2, total HSF1, p-Ser362, and HSP72 levels compared with lines that maintain full-length neurofibromin expression. (B) IF staining confirmed HSF1 overexpression in cells without neurofibromin. Insets show nuclear HSF1 staining. DAPI counterstaining is presented to visualize cell nuclei. All images were acquired at identical magnification. Scale bars: 25 μm; 5 μm (insets). (C) Immunoblotting of cross-linked cell lysates demonstrated increased activation-associated trimeric (Tri) versus inactive monomeric (Mon) forms of HSF1 in MPNST cells without NF1 compared with lysates from NF1-expressing cell lines. The trimeric/monomeric ratio in lysates, as measured by densitometry, is indicated. (D and E) MEK inhibition reduced p-Ser326 and HSF1 nuclear translocation in human MPNST cells. S462 cells were treated with 20 μM U0126 overnight. Total p-Ser326 and nuclear HSF1 were detected by immunoblotting.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts